Onset
Not established; no human data exists.
Protocol / Research Dosing Guide
AHK-Cu Dosage Guide: Research Evidence, Reconstitution and Safety
An evidence-organized AHK-Cu guide that separates the copper peptide's cell-based research from vendor claims, and keeps every human use question labeled honestly.
Last reviewed September 16, 202615 minute readResearch information only
Level 2 — Cell and preclinical evidenceNo published human trialsNot FDA approved
AHK-Cu Quick Start
AHK-Cu is a copper-binding tripeptide (alanine-histidine-lysine complexed with copper), closely related to GHK-Cu. Published work is limited to cell-culture studies — mostly human dermal papilla and fibroblast experiments reporting effects on growth-factor signaling and collagen-related markers. No human trial, animal dosing study, or pharmacokinetic study of AHK-Cu was identified.
Why researchers care
Hair follicle and skin fibroblast research
Class
Copper tripeptide, Ala-His-Lys-Cu (GHK-Cu analogue)
Route reported
Research vials and cosmetic-formulation products are sold
Cycle length
Not established
Regulatory status
Not FDA approved; research-use and cosmetic-ingredient contexts only
Loading supplier information
AHK-Cu Dosing Protocol and Schedule
No supplied coverage source establishes any human amount, schedule, or cycle for AHK-Cu. Vendor listings present a 50 mg research vial without a studied regimen. Every field below that lacks direct evidence is marked not established.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Human schedule | Not established | No human study exists |
| Cell-culture concentrations | Experimental ranges vary by study | Laboratory context only — not a body dose |
| Cycle or rest interval | Not established | No study defines one |
Cell-culture concentrations cannot be converted into human amounts. No validated schedule, cycle, or rest period exists for AHK-Cu.
AHK-Cu Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
AHK-Cu Reconstitution Calculator
Vial-format concentration math
Concentration
20 mg/mL
Draw volume
0.125 mL
U-100 units
12.5
Mathematical draws
20
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take AHK-Cu: Morning or Night?
Morning or evening?
Not established. No human-use study exists.
Daily or intermittent?
Not established.
With food?
Not applicable to a vial format and not established for any format.
Missed amount?
No validated replacement or doubling procedure exists.
AHK-Cu Route Comparison
| Route | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous vial | Research vials are marketed | No human safety or pharmacokinetic study |
| Topical or cosmetic | Copper peptides appear in cosmetic formulations | AHK-Cu-specific absorption is not established |
| Oral | Not established | No exposure data |
| Route conversion | None available | Formats are not interchangeable |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
AHK-Cu Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human half-life | Not established | No human PK study |
| Animal half-life | Not established | No animal PK study identified |
| Skin penetration | Not established for AHK-Cu | Related copper-peptide data does not substitute |
| Frequency | Not established | No studied regimen |
AHK-Cu Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Any human route | Not established | — | No human study | No |
| Cell culture | Study-specific concentrations | — | Laboratory research | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
AHK-Cu Reconstitution Guide
Concentration: 20 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 2.5 mg | 0.125 mL | 12.5 units |
| 5 mg | 0.25 mL | 25 units |
| 7.5 mg | 0.375 mL | 37.5 units |
- 1.Confirm the exact vial label and total quantity.
- 2.Record the measured diluent volume.
- 3.Clean the vial stopper.
- 4.Add liquid slowly along the vial wall.
- 5.Swirl gently; do not shake.
- 6.Inspect for cloudiness, discoloration, or particles.
- 7.Label the calculated concentration and preparation date.
- 8.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How AHK-Cu Works
Copper tripeptide family
AHK-Cu is an analogue of GHK-Cu, carrying copper into cell-culture systems.
AHK-Cu Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved; research-use and cosmetic-ingredient contexts only
- No published human trial of AHK-Cu was identified.
- No published animal dosing study of AHK-Cu was identified.
- Published work is limited to cell-culture experiments.
- AHK-Cu is not FDA approved and has no established medical use.
Who Should Avoid AHK-Cu?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Known ingredient sensitivity
Identity and excipient uncertainty
Wilson disease or copper-metabolism disorders
Copper load is unstudied
Concurrent medicines
No interaction studies
Long-term or repeated use
No safety data
AHK-Cu Side Effects, Risks and Safety
Injection-site or skin irritationAnecdotal
Important limitation: No controlled incidence data.
Copper accumulationTheoretical
Important limitation: No human copper-balance study.
Allergic responseUnknown
Important limitation: No characterized safety dataset.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
AHK-Cu Timeline and Monitoring
Peak effect
Not established.
Cycle length
Not established.
Monitoring
No validated monitoring schedule or stopping rule exists.
AHK-Cu Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Hair growth support | Not established | Cell-culture dermal papilla research | No human study |
| Skin or collagen support | Not established | Cell-culture fibroblast research | No human study |
| Anti-aging claims | Not established | Marketing extrapolation | No controlled data |
AHK-Cu Storage and Handling
Unreconstituted vial
No AHK-Cu-specific stability study was identified; follow the exact product label.
Prepared vial
No validated AHK-Cu storage duration was identified.
Cosmetic formulation
Follow the product-specific label; no universal condition is established.
Appearance
Cloudiness, discoloration, or particles do not establish safe usability.
AHK-Cu Troubleshooting
Solution appears cloudy
Stop and seek qualified product guidance; appearance cannot confirm sterility.
Calculated units look wrong
Recheck vial quantity, diluent volume, target unit, and U-100 conversion.
Conflicting amounts online
No studied human amount exists; community figures are not validated.
Unexpected symptoms occur
No AHK-Cu safety protocol exists; seek licensed clinical review.
A scheduled amount is missed
No validated missed-amount procedure exists.
AHK-Cu Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| AHK-Cu | Ala-His-Lys copper tripeptide | Cell-culture studies only | Not approved |
| GHK-Cu | Gly-His-Lys copper tripeptide | Cell and cosmetic-formulation research | Not approved |
| Glow blend | GHK-Cu + BPC-157 + TB-500 vendor blend | No direct studies | Not approved |
AHK-Cu Frequently Asked Questions
What is AHK-Cu?
A copper-binding tripeptide (Ala-His-Lys-Cu), an analogue of GHK-Cu, studied only in cell-culture research.
Has AHK-Cu been studied in humans?
No published human trial was identified.
Has it been studied in animals?
No published animal dosing study was identified.
Is it FDA approved?
No.
What is the correct human dose?
Not established — no human study exists.
What is its half-life?
Not established.
Is AHK-Cu the same as GHK-Cu?
No. They are related copper peptides with different amino-acid sequences, and evidence does not transfer between them.
Is a cycle or rest period established?
No.
What does the calculator do?
It converts entered vial and liquid values into concentration and volume math only.
Sources and Research
Vendor listing
1. AHK-Cu 50mg product listing
Vendor listing confirming vial size and price; not evidence of effect.
Open direct sourceCell research index
2. AHK-Cu and dermal papilla cell research
Cell-culture study context for hair follicle signaling claims; not a human study.
Open direct sourceMissing information flagged for review
- Human trial of any kind: Not established
- Animal dosing study: Not established
- Human dose, route, and frequency: Not established
- Half-life and pharmacokinetics: Not established
- Validated cycle and rest period: Not established
- Compound-specific stability data: Not established
- Long-term safety: Not established
- Drug interactions: Not established